Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Laser Moxibustion Appears to Lessen Cancer-Related Fatigue

August 10, 2016
By Dave Levitan
Article

An infrared laser-based version of the traditional Chinese medicinal technique known as moxibustion was found to improve cancer-related fatigue.

An infrared laser-based version of the traditional Chinese medicinal technique known as moxibustion was found to improve cancer-related fatigue compared to a sham version of the technique in a new randomized study.

“Clinical treatments of cancer-related fatigue have been unsatisfactory, without recognized and effective drug treatments,” wrote study authors led by Xueyong Shen, MD, of the Shanghai University of Traditional Chinese Medicine. Moxibustion involves burning of an herb known as moxa on or above the skin at acupoints; there have been few high-quality studies done on this technique, though it has been used for thousands of years to treat a variety of conditions.

In the new study, the researchers used a version of moxibustion involving a 10.6 µm infrared laser, which they wrote mimics the effects of traditional moxibustion but eliminates some of its shortcomings including smoke and dosage control difficulties. The trial included 78 patients (61 of whom completed the full study) with cancer-related fatigue; patients were randomized to either three 20-minute sessions per week for 4 weeks or a sham version of the same treatments, without infrared laser output. The results were published online ahead of print in Cancer.

There were 30 patients in the moxibustion group and 31 in the sham group available for analysis. At baseline, cancer-related fatigue as measured using the Brief Fatigue Inventory was similar between the groups (4.67 in the laser group and 5.03 in the sham group; P = .407).

By week 2 of the study, fatigue scores had dropped to 3.80 in the moxibustion group, compared with 4.70 in the sham group (P = .044). At the end of the 4 weeks of treatment, the difference was more pronounced, at 3.01 vs 4.40 (P = .002). The difference remained at an 8-week follow-up visit as well, at 3.03 vs 4.26 (P = .006).

The authors reported no serious adverse events in either group. Three patients in the laser group had localized erythema, though this resolved within 3 days.

“The findings of the current study suggest that 10.6-μm infrared laser moxibustion holds therapeutic potential as a potentially safe and effective non-pharmacological intervention for cancer-related fatigue,” they concluded. The study was limited by its small size, the significant dropout rate mostly related to worsening condition of the patients, the lack of long-term follow-up, and no usual-care group for comparison.

The authors wrote that longer studies are needed to confirm the benefit of the treatment, as is further research to elucidate what the mechanism behind the clinical effect might be.

Recent Videos
2 experts are featured in this series.
2 experts are featured in this series.
Related Content
Advertisement

The median disease-free survival was 9.41 months in the TAS-102 cohort compared with 5.75 months in the synthetic control arm.

Though TAS-102 Achieved ctDNA Clearance, More Work is Needed

Tim Cortese
August 27th 2025
Article

TAS-102 had a significant impact, achieving ctDNA clearance, in patients with colorectal cancer with ctDNA-defined MRD.


Geraldine O’Sullivan Coyne, MD, MRCPI, PhD, discusses how the START center may expand access to novel therapies for patients who reside in a community.

START Center Aims to Bring New Cancer Treatments, Trials to The Community

Geraldine O’Sullivan Coyne, MD, MRCPI, PhD
August 25th 2025
Podcast

Geraldine O’Sullivan Coyne, MD, MRCPI, PhD, discusses how the START center may expand access to novel therapies for patients who reside in a community.


Data from KEYNOTE-585 showed that adding pembrolizumab to chemotherapy did not negatively impact health-related quality of life vs placebo/chemotherapy.

Pembrolizumab Combo Improves pCR Rate in Advanced Gastric/GEJ Cancer

Russ Conroy
August 27th 2025
Article

Data from KEYNOTE-585 showed that adding pembrolizumab to chemotherapy did not negatively impact health-related quality of life vs placebo/chemotherapy.


Beyond the Tumor: Addressing Body Image in Oncology

Beyond the Tumor: Addressing Body Image in Oncology

Daniel C. McFarland, DO;Michelle Fingeret, PhD
August 18th 2025
Podcast

Daniel C. McFarland, DO; and Michelle Fingeret, PhD, discuss the issue of body image in patients with cancer.


Stenoparib Receives FDA Fast Track Designation in Advanced Ovarian Cancer

Stenoparib Receives FDA Fast Track Designation in Advanced Ovarian Cancer

Ariana Pelosci
August 27th 2025
Article

The novel treatment was evaluated in a phase 2 trial and saw a clinical benefit in patients with advanced ovarian cancer.


Pioneer of Supportive Care Highlights Additional Needs in The Space

Pioneer of Supportive Care Highlights Additional Needs in The Space

Ariana Pelosci
August 27th 2025
Article

Declan Walsh, MD, highlighted how the supportive and palliative care space has evolved since he first began working in the field.

Related Content
Advertisement

The median disease-free survival was 9.41 months in the TAS-102 cohort compared with 5.75 months in the synthetic control arm.

Though TAS-102 Achieved ctDNA Clearance, More Work is Needed

Tim Cortese
August 27th 2025
Article

TAS-102 had a significant impact, achieving ctDNA clearance, in patients with colorectal cancer with ctDNA-defined MRD.


Geraldine O’Sullivan Coyne, MD, MRCPI, PhD, discusses how the START center may expand access to novel therapies for patients who reside in a community.

START Center Aims to Bring New Cancer Treatments, Trials to The Community

Geraldine O’Sullivan Coyne, MD, MRCPI, PhD
August 25th 2025
Podcast

Geraldine O’Sullivan Coyne, MD, MRCPI, PhD, discusses how the START center may expand access to novel therapies for patients who reside in a community.


Data from KEYNOTE-585 showed that adding pembrolizumab to chemotherapy did not negatively impact health-related quality of life vs placebo/chemotherapy.

Pembrolizumab Combo Improves pCR Rate in Advanced Gastric/GEJ Cancer

Russ Conroy
August 27th 2025
Article

Data from KEYNOTE-585 showed that adding pembrolizumab to chemotherapy did not negatively impact health-related quality of life vs placebo/chemotherapy.


Beyond the Tumor: Addressing Body Image in Oncology

Beyond the Tumor: Addressing Body Image in Oncology

Daniel C. McFarland, DO;Michelle Fingeret, PhD
August 18th 2025
Podcast

Daniel C. McFarland, DO; and Michelle Fingeret, PhD, discuss the issue of body image in patients with cancer.


Stenoparib Receives FDA Fast Track Designation in Advanced Ovarian Cancer

Stenoparib Receives FDA Fast Track Designation in Advanced Ovarian Cancer

Ariana Pelosci
August 27th 2025
Article

The novel treatment was evaluated in a phase 2 trial and saw a clinical benefit in patients with advanced ovarian cancer.


Pioneer of Supportive Care Highlights Additional Needs in The Space

Pioneer of Supportive Care Highlights Additional Needs in The Space

Ariana Pelosci
August 27th 2025
Article

Declan Walsh, MD, highlighted how the supportive and palliative care space has evolved since he first began working in the field.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.